Objective:

The aim of this study was to evaluate the targeting ability of metuximab against other tumors.

Methods:

HAb18F(ab)

2

was labeled with

125

I

and Nano-SPECT/CT was used to observe the targeting effect of HAb18F(ab)

2

on human hepatocellular carcinoma cell line SMMC-7721

pancreatic carcinoma cell line SW1990 and lung cancer cell line A549 continuously. The tumor-to-muscle (T/M) ratio was further calculated with InViv

o Scope software. The uptake of

125

I-HAb18F(ab)

2

by different tumors was compared.

Results:

SPECT/CT imaging showed that human cancer cell line SMMC-7721

SW1990 and A549 all displayed high uptake of

125

I-HAb18F(ab)

2

. The obvious tumor radioactivity concentration and low radioactivity background of whole body made the high image contrast. The T/M ratio in SMMC-7721

SW1990 and A549 was 432

234 and 26

respectively. The retention of

125

I-HAb18F(ab)

2

in SW1990 and SMMC-7221 was both as long as 9 d.

Conclusion:

All three types of tumors display high uptake of HAb18F(ab)

2

and HAb18F(ab)

2

is able to be detained long in the three tumors. HAb18F(ab)

2

showes the potential to be further applied in the diagnosis and treatment of other tumors besides the liver cancer.